Sandrini Massimo, Vizzardi Valerio, Valerio Francesca, Ravera Sara, Manili Luigi, Zubani Roberto, Lucca Bernardo J A, Cancarini Giovanni
O.U. of Nephrology, A.S.S.T. Spedali Civili di Brescia, Piazzale Spedali Civili, 1, 25123, Brescia, Italy.
Università di Brescia, Brescia, Italy.
J Nephrol. 2016 Dec;29(6):871-879. doi: 10.1007/s40620-016-0344-z. Epub 2016 Aug 31.
Incremental dialysis consists in prescribing a dialysis dose aimed towards maintaining total solute clearance (renal + dialysis) near the targets set by guidelines. Incremental peritoneal dialysis (incrPD) is defined as one or two dwell-times per day on CAPD, whereas standard peritoneal dialysis (stPD) consists in three-four dwell-times per day.
Single-centre cohort study. Enrollement period: January 2002-December 2007; end of follow up (FU): December 2012.
incident patients with FU ≥6 months, initial residual renal function (RRF) 3-10 ml/min/1.73 sqm BSA, renal indication for PD.
Median incrPD duration was 17 months (I-III Q: 10; 30). There were no statistically significant differences between 29 patients on incrPD and 76 on stPD regarding: clinical, demographic and anthropometric characteristics at the beginning of treatment, adequacy indices, peritonitis-free survival (peritonitis incidence: 1/135 months-patients in incrPD vs. 1/52 months-patients in stPD) and patient survival. During the first 6 months, RRF remained stable in incrPD (6.20 ± 2.02 vs. 6.08 ± 1.47 ml/min/1.73 sqm BSA; p = 0.792) whereas it decreased in stPD (4.48 ± 2.12 vs. 5.61 ± 1.49; p < 0.001). Patient survival was affected negatively by ischemic cardiopathy (HR: 4.269; p < 0.001), peripheral and cerebral vascular disease (H2.842; p = 0.006) and cirrhosis (2.982; p = 0.032) and positively by urine output (0.392; p = 0.034). Hospitalization rates were significantly lower in incrPD (p = 0.021). Eight of 29 incrPD patients were transplanted before reaching full dose treatment.
IncrPD is a safe modality to start PD; compared to stPD, it shows similar survival rates, significantly less hospitalization, a trend towards lower peritonitis incidence and slower reduction of renal function.
递增式透析是指设定透析剂量,旨在使总溶质清除率(肾脏 + 透析)接近指南设定的目标。递增式腹膜透析(incrPD)定义为持续性非卧床腹膜透析(CAPD)每天进行一或两次留腹,而标准腹膜透析(stPD)则是每天进行三或四次留腹。
单中心队列研究。入组时间:2002年1月至2007年12月;随访结束(FU):2012年12月。
随访时间≥6个月的初发患者,初始残余肾功能(RRF)为3 - 10 ml/min/1.73平方米体表面积,有腹膜透析的肾脏指征。
incrPD的中位持续时间为17个月(第一至第三四分位数:10;30)。29例接受incrPD治疗的患者与76例接受stPD治疗的患者在以下方面无统计学显著差异:治疗开始时的临床、人口统计学和人体测量学特征、充分性指标、无腹膜炎生存期(腹膜炎发生率:incrPD组为1/135患者月,stPD组为1/52患者月)以及患者生存率。在最初6个月,incrPD组的RRF保持稳定(6.20 ± 2.02 vs. 6.08 ± 1.47 ml/min/1.73平方米体表面积;p = 0.792),而stPD组的RRF则下降(4.48 ± 2.12 vs. 5.61 ± 1.49;p < 0.001)。缺血性心脏病(HR:4.269;p < 0.001)、外周和脑血管疾病(HR:2.842;p = 0.006)以及肝硬化(HR:2.982;p = 0.032)对患者生存率有负面影响,而尿量(HR:0.392;p = 0.034)则有正面影响。incrPD组的住院率显著更低(p = 0.021)。29例incrPD患者中有8例在达到全剂量治疗前接受了移植。
incrPD是开始腹膜透析的一种安全方式;与stPD相比,它显示出相似的生存率、显著更少的住院次数、腹膜炎发生率有降低趋势以及肾功能下降更缓慢。